Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1989 1
1990 1
1991 2
1992 1
1993 3
1995 4
1996 4
1997 5
1998 1
1999 3
2001 3
2002 3
2003 3
2004 3
2005 2
2006 3
2007 4
2008 3
2009 1
2010 4
2011 1
2012 2
2013 4
2014 10
2015 8
2016 8
2017 5
2018 14
2019 10
2020 21
2021 15
2022 24
2023 22
2024 22
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators. Flack JM, et al. N Engl J Med. 2025 Oct 9;393(14):1363-1374. doi: 10.1056/NEJMoa2507109. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888730 Free PMC article. Clinical Trial.
Mechanical Properties of Three-Dimensional Printed Provisional Resin Materials for Crown and Fixed Dental Prosthesis: A Systematic Review.
Alzahrani SJ, Hajjaj MS, Azhari AA, Ahmed WM, Yeslam HE, Carvalho RM. Alzahrani SJ, et al. Bioengineering (Basel). 2023 May 31;10(6):663. doi: 10.3390/bioengineering10060663. Bioengineering (Basel). 2023. PMID: 37370594 Free PMC article. Review.
The systematically extracted data included the researcher's name(s), publication year, evaluation method, number of samples, types of materials, and study outcome. ...
The systematically extracted data included the researcher's name(s), publication year, evaluation method, number of samples, t …
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1119-1129. doi: 10.2215/CJN.0000000000000498. Epub 2024 Jun 27. Clin J Am Soc Nephrol. 2024. PMID: 40179340 Free PMC article. Clinical Trial.
We derived a multivariable logistic regression model to predict hospitalization (reflecting frailty) and assessed empagliflozin's risk-benefit profile in a post hoc analysis of the double-blind, placebo-controlled EMPA-KIDNEY trial. ...
We derived a multivariable logistic regression model to predict hospitalization (reflecting frailty) and assessed empagliflozin's ris …
218 results